RAPT Articles, RAPT Therapeutics Inc.

Lisata Therapeutics, Inc.'s (NASDAQ: LSTA) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treat...

Beam Therapeutics Inc. (NASDAQ: BEAM) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the ...

Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its ...

Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investiga...

On Thursday, RAPT Therapeutics Inc. (NASDAQ:RAPT) announced that it has decided to close and unblind both its Phase 2b trial of zeln...

Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duol...

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therap...